Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

Movement Disorders

Volumn 13, Issue 1, 1998, Pages 39-45

  Rascol, Olivier ^a   Brooks, David J ^b   Brunt, Ehrout R ^c   Korczyn, Amos D ^d   Poewe, Warner H ^e   Stocchi, Fabrizzio ^f  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine agonist; Double blind, controlled study; Early Parkinson's disease; Levodopa; Ropinirole

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; ROPINIROLE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; SWEATING; TREMOR; VERTIGO; VOMITING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031965147     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130111     Document Type: Article

References (37)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;i:292-296.
3. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506.
4. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
5. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353:246-250.
6. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
7. Blin J, Bonnet A-M. Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
8. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
9. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1021-1023.
10. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
11. Rinne UK. Brief communication: early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
12. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
13. Factor SA, Weiner WJ. Viewpoint: early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-262.
14. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11:200-206.
15. Rascol A, Montastruc JL, Rascol O. Should dopamine agonists be given early or late in the treatment of Parkinson's disease? Can J Neurol Sci 1984;11:229-232.
16. Hachinski V. Timing of levodopa therapy. Arch Neurol 1986;43:407.
17. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405.
18. 2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
19. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marie C, Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet 1990;336:316-317.
20. 2 agonist SK&F 101468. Lancet 1989;i:1445-1446.
21. Kleedorfer B, Stern GM, Lees AJ, Bottomley JM, Sree-Haran N. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:10.
22. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-245.
23. Lees AJ. The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
24. Fahn S, Elton R and Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, eds. Recent developments in Parkinson's disease, vol 2. New York: Raven Press. 1987:153-163.
25. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
26. Guy W. ECDEU assessment manual for psychopharmacology. NIMH Publ. DHEW Publ. No. (Adm.) 76-338. Revised 1976:217-222.
27. Laroche J. An alternative analysis of motor score in the assessment of Parkinson's disease. In: Douglas J, ed. Macclesfield: statisticians in the pharmaceutical industry. 1995 PSI Conference Report. Blackpool, UK, 1996:52-53.
28. Hoehn M, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985;35:199-206.
29. Lieberman A. Long-term experience with selegiline and levodopa in Parkinson's disease. Neurology 1992;42(suppl 4):32-36.
30. Poewe W. Exkurs: Wirkverlust und 'Therapieresistenz.' In: Riederer P, Laux G, Pöldinger W, eds. Neuro-Psychopharmaka, vol 5. Vienna: Springer-Verlag, 1992:145-157.
31. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991;18:275-278.
32. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
33. Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of 'de novo' Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.
34. Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472.
35. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
36. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study.
37. 2 receptors? Trends Pharmacal Sci 1986;7:224-225.